Disclaimer: The data in this column come from either mainstream news
media sources or scientific research published in peer-reviewed
journals (each category can be determined by following the links in
the reference section). This column's author acknowledges the cultural
bias of the world scientific community in its belief that the
scientific method is the most viable available alternative for
assessing COVID-19 and its effects in an objective manner through a
structured process of observable and repeatable hypothesis testing.
Summary: Hospitalizations from COVID-19 rose for an eighth straight
week to 18,871 people/week see "COVID Hospitalizations Rise for Eighth
Week in a Row" under Virology & Epidemiology).
Moderna says its upcoming COVID-19 vaccine should work against the
BA.2.86 variant that has caused worry about a possible surge in cases
(see "New Moderna Vaccine to Work Against Recent COVID Variant" under
Vaccomes, Treatment & Testing).
COVID vaccines will have a new formulation this year, according to a
decision announced today by the US Food and Drug Administration that
will focus efforts on circulating variants. The move pushes last
year's bivalent vaccines out of circulation because they will no
longer be authorized for use in the United States (see "New COVID
Vaccines Force Bivalents Out" under Policy).
The CDC is not specifically saying whether long COVID patients should
get the new COVID boosters, flu shots, or RSV vaccines, and the Food
and Drug Administration (FDA) referred similar questions to the CDC
(see "Should Long COVID Patients Get the Flu, RSV, and New Booster
Shots?" under Policy).
Research continues to show that early intervention with antibiotics
reduces the risk of fatality from COID-19 (see "Early Empiric
Antibiotic Use in Patients Hospitalized With COVID-19" under Vaccines,
Treatment & Testing).
In ICU-patients ≥70 years old, COVID-19 is associated with greater
mortality rates than bacterial or viral pneumonia (see "Increased
Mortality in ICU Patients ≥70 Years Old With COVID-19 Compared to
Patients With Other Pneumonias" under COVID Complications).
After the US Food and Drug Administration authorized new monovalent
COVID vaccines, the CDC recommended the new booster vaccinations for
everyone (see "Universal Monovalent COVID Vaccines Backed by CDC"
under Policy).
About 103 million Americans had COVID-19, and about a third of those
led to long COVID. New data indicate that some cases of long COVID-19
might be going unidentified because the patient's initial infection
wasn't detected (see "Some People With Long COVID Tested Negative for
COVID-19" under COVID Complications).
Although SARS-CoV-2 infection among young children typically results
in mild infection, it can result in serious illness, including
multisystem inflammatory syndrome in children, long-term sequalae, and
death. mRNA COVID-19 vaccination provides protection against
symptomatic SARS-CoV-2 infection for at least 4 months after
vaccination among children aged 3–5 years (see "Safety Monitoring of
mRNA COVID-19 Vaccine Third Doses Among Children Aged 6 Months–5
Years" under Vaccines, Treatment & Testing).
A new meta-analysis has shown that SGLT2 inhibitors do not lead to
lower 28-day all-cause mortality compared with usual care or placebo
in patients hospitalized with COVID-19 (see "SGLT2-inhibitors: No
Benefit in Hospitalized COVID-19" under Vaccines, Treatment &
Testing).
The COVID-19 booster vaccine typically causes transient, clinically
insignificant elevations in glucose levels in people with type 1
diabetes (see "COVID Booster May Transiently Raise Glucose Levels in
T1D" under Vaccines, Treatment & Testing).
"Cost May Lead Many to Skip COVID Testing: Why That's a Problem" (see
under Media News).
The May 11, 2023 termination of the PHE has made it increasingly
difficult to accurately track COVID-19 new cases or fatalities.
However, new variants of concern continue to emerge, with consequent
infections and deaths.
Since the termination of the PHE, data on vaccination rates are no
longer being tracked. The last known US COVID-19 vaccination rates
(May 10, 2023) are as follows: full
vaccination (two initial doses) 69.3%; at least one updated booster
dose: 17% (see "Track Covid-19 in the U.S." under
Vaccines, Treatment & Testing). "Our World in Data" stopped trying to
track US booster rates on August 30, 2022 and shows a flat line since
then.
#psychology #counseling #socialwork #psychotherapy #research
@[email protected] @[email protected] @[email protected]
@[email protected] #Vaccines #COVID #longcovid #science #medicine
#covid19 #coronavirus #sars-cov-2 #covidisnotover #CDC
@[email protected] @[email protected] @[email protected]
#depression #anxiety #sleep #brainfog #stillnotover
.
.
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can subscribe at @[email protected]
